Corina Taitt

3.3k total citations · 2 hit papers
14 papers, 1.2k citations indexed

About

Corina Taitt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Corina Taitt has authored 14 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 3 papers in Genetics. Recurrent topics in Corina Taitt's work include Lung Cancer Treatments and Mutations (8 papers), HER2/EGFR in Cancer Research (5 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). Corina Taitt is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), HER2/EGFR in Cancer Research (5 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). Corina Taitt collaborates with scholars based in United States, Japan and Italy. Corina Taitt's co-authors include Juan Manuel Sepúlveda-Sánchez, Michael Weller, Solmaz Sahebjam, David A. Reardon, Surasak Phuphanich, Michael Carleton, Michael Lim, Alba A. Brandes, John H. Sampson and Paul de Souza and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Corina Taitt

14 papers receiving 1.2k citations

Hit Papers

Effect of Nivolumab vs Bevacizumab in Patients With Recur... 2020 2026 2022 2024 2020 2022 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
    2020 946 citations David A. Reardon, Alba A. Brandes et al. JAMA Oncology profile →
  2. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
    2022 121 citations Charles A. Powell, Shanu Modi et al. ESMO Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Corina Taitt United States 7 659 621 396 324 230 14 1.2k
Orsolya Rajky Austria 9 786 1.2× 661 1.1× 444 1.1× 478 1.5× 199 0.9× 14 1.3k
Jacob Ruzevick United States 18 485 0.7× 370 0.6× 351 0.9× 249 0.8× 228 1.0× 49 1.1k
Brian Ahn United States 12 520 0.8× 499 0.8× 734 1.9× 263 0.8× 280 1.2× 15 1.4k
George Ansstas United States 17 471 0.7× 428 0.7× 277 0.7× 175 0.5× 337 1.5× 75 1.1k
Carlos de Andrea Spain 10 658 1.0× 303 0.5× 519 1.3× 234 0.7× 231 1.0× 23 1.1k
Dimitrios Mathios United States 18 608 0.9× 318 0.5× 561 1.4× 212 0.7× 315 1.4× 42 1.4k
Jillian Phallen United States 13 494 0.7× 282 0.5× 372 0.9× 242 0.7× 315 1.4× 31 1.1k
Rikke Hedegaard Dahlrot Denmark 18 266 0.4× 544 0.9× 215 0.5× 180 0.6× 443 1.9× 60 1.1k
Lukas Bunse Germany 15 372 0.6× 318 0.5× 322 0.8× 75 0.2× 224 1.0× 44 778
Álvaro López‐Janeiro Spain 11 335 0.5× 286 0.5× 303 0.8× 139 0.4× 159 0.7× 21 730

Countries citing papers authored by Corina Taitt

Since Specialization
Citations

This map shows the geographic impact of Corina Taitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corina Taitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corina Taitt more than expected).

Fields of papers citing papers by Corina Taitt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corina Taitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corina Taitt. The network helps show where Corina Taitt may publish in the future.

Co-authorship network of co-authors of Corina Taitt

This figure shows the co-authorship network connecting the top 25 collaborators of Corina Taitt. A scholar is included among the top collaborators of Corina Taitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corina Taitt. Corina Taitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Rugo, Hope S., Eriko Tokunaga, Hiroji Iwata, et al.. (2025). Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis. Annals of Oncology. 36(11). 1389–1399. 1 indexed citations
2.
Rugo, H. S., Eriko Tokunaga, Hiroji Iwata, et al.. (2024). 267MO Pooled analysis of trastuzumab deruxtecan (T-DXd) retreatment (RTx) after recovery from grade (Gr) 1 interstitial lung disease/pneumonitis (ILD). ESMO Open. 9. 103326–103326. 3 indexed citations
3.
Nishino, Mizuki, Masahiko Kusumoto, Alexander A. Bankier, et al.. (2023). Trastuzumab Deruxtecan‒Related Interstitial Lung Disease/Pneumonitis: Computed Tomography Imaging Patterns to Guide Diagnosis and Management. JCO Precision Oncology. 7(7). e2300391–e2300391. 6 indexed citations
4.
Powell, Charles A., Shanu Modi, Hiroji Iwata, et al.. (2022). Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 7(4). 100554–100554. 121 indexed citations breakdown →
5.
Powell, Charles A., Shanu Modi, Hiroji Iwata, et al.. (2021). 92O Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd). Annals of Oncology. 32. S61–S62. 12 indexed citations
6.
Powell, Charles A., Shanu Modi, Hiroji Iwata, et al.. (2021). Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies. Cancer Research. 81(13_Supplement). CT167–CT167. 11 indexed citations
7.
Hackshaw, Michelle D., Heather E. Danysh, Jasmeet Singh, et al.. (2020). Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 183(1). 23–39. 66 indexed citations
8.
Powell, Charles A., D. Ross Camidge, Shanu Modi, et al.. (2020). 289P Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies. Annals of Oncology. 31. S357–S358. 18 indexed citations
9.
Reardon, David A., Alba A. Brandes, Antonio Omuro, et al.. (2020). Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. JAMA Oncology. 6(7). 1003–1003. 946 indexed citations breakdown →
10.
Weller, Michael, David A. Reardon, Alba A. Brandes, et al.. (2019). ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. Neuro-Oncology. 21(Supplement_6). vi12–vi12. 1 indexed citations
11.
Eggermont, Alexander M.M., Vanna Chiarion‐Sileni, Jean‐Jacques Grob, et al.. (2016). melanoma and other skin tumours Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. Annals of Oncology. 27. vi574–vi574. 6 indexed citations
12.
Huhn, Richard D., et al.. (2015). A phase 3 open-label, randomized, multicenter study of Imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer.. Journal of Clinical Oncology. 33(3_suppl). TPS787–TPS787. 2 indexed citations
13.
Huhn, Richard D., et al.. (2015). A phase 3 open-label, randomized, multicenter study of imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer.. Journal of Clinical Oncology. 33(15_suppl). TPS3635–TPS3635. 1 indexed citations
14.
Schneller, Folker, Walburga Engel-Riedel, Michael Thomas, et al.. (2015). Safety of Imprime PGG, a novel innate immune cell modulator, in adults with stage IV non-small cell lung cancer: an integrated analysis of two randomized phase 2 studies.. Journal of Clinical Oncology. 33(15_suppl). 3071–3071. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Orsolya Rajky Breakdown of academic impact, for papers by Jacob Ruzevick Breakdown of academic impact, for papers by Brian Ahn Breakdown of academic impact, for papers by George Ansstas Breakdown of academic impact, for papers by Carlos de Andrea Breakdown of academic impact, for papers by Dimitrios Mathios Breakdown of academic impact, for papers by Jillian Phallen Breakdown of academic impact, for papers by Rikke Hedegaard Dahlrot Breakdown of academic impact, for papers by Lukas Bunse Breakdown of academic impact, for papers by Álvaro López‐Janeiro
Rankless by CCL
2026